Combinations of histone deacetylase inhibitors and immunomodulatory drugs
The invention relates to combinations comprising an HDAC inhibitor and an immunomodulatory drug for the treatment of lymphoma in a subject in need thereof. Also provided herein are methods for treating lymphoma in a subject in need thereof comprising administering to the subject an effective amount of one of the above combinations.
1. A method for treating lymphoma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical combination comprising a histone deacetylase 6 (HDAC6) specific inhibitor or a pharmaceutically acceptable salt thereof, and an immunomodulatory drug (IMiD) or a pharmaceutically acceptable salt thereof, wherein the HDAC6 specific inhibitor is
or a pharmaceutically acceptable salt thereof; and
wherein the immunomodulatory drug is
or a pharmaceutically acceptable salt thereof, or
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the immunomodulatory drug is:
or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein the subject was previously refractory to a monotherapy comprising the immunomodulatory drug.
4. The method of claim 1 , wherein the HDAC inhibitor and the immunomodulatory drug are administered in separate dosage forms.
5. The method of claim 1 , wherein the HDAC inhibitor and the immunomodulatory drug are administered in a single dosage form.
6. The method of claim 1 , wherein the HDAC inhibitor and the immunomodulatory drug are administered at different times.
7. The method of claim 1 , wherein the HDAC inhibitor and the immunomodulatory drug administered at substantially the same time.